Developing new treatment options for cancer patients
Cardiff’s mission is to develop new treatment options for cancer patients in indications with the greatest medical need. The company’s goal is to overcome resistance, improve response to treatment, and increase overall survival. Cardiff is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
